Brainomix, an AI-focused medtech company, has secured £14M ($18M) in Series C funding to enhance its imaging technology. This investment will drive the expansion of its stroke and lung fibrosis AI solutions, increasing their reach and impact.
This latest funding round brings Brainomix’s total investment to £44M ($57M). Existing investors Parkwalk Advisors, the UK’s largest growth EIS fund manager, and the Boehringer Ingelheim Venture Fund (BIVF) co-led the round. New investor Hostplus joined via the IP Group Hostplus Innovation Fund. Hostplus, an Australian industry superannuation fund, manages over AUD$120B. LifeSci Capital also participated. This investment will support technological advancements and fund clinical validation studies to demonstrate the efficacy of AI-driven diagnostics.
How Brainomix is transforming stroke diagnosis with AI imaging
When a stroke patient arrives at a hospital, quick and accurate imaging is crucial. Brainomix’s AI platform, Brainomix 360 Stroke, automates brain scan analysis, helping clinicians make faster and more informed decisions. This technology has led to a 50% increase in patients receiving mechanical thrombectomy, a key stroke treatment that significantly reduces disability and improves recovery outcomes.
Brainomix founder backgrounds
Brainomix was founded at the University of Oxford by Dr. Michalis Papadakis and Professor Alastair Buchan. Dr. Papadakis, the CEO, holds a BSc in Biochemistry from Imperial College London and a PhD in neurosciences from UCL School of Pharmacy. He previously led Oxford’s preclinical stroke lab, focusing on pioneering stroke research. Professor Buchan, a leading expert in Stroke Medicine at Oxford, developed ASPECTS, a globally used scoring system for assessing CT brain scans in stroke diagnosis. Their combined expertise has positioned Brainomix as a leader in AI-driven stroke care.
Addressing critical gaps in stroke care
Despite life-saving treatments being available, up to 80% of eligible patients miss out due to challenges in brain CT scan interpretation, especially in primary stroke units that lack stroke specialists. Many hospitals struggle with limited expertise in reading complex imaging data, leading to missed treatment opportunities. Brainomix’s AI-powered imaging solutions aim to eliminate these barriers, ensuring timely and accurate diagnoses while reducing human error and improving patient outcomes. By making AI-assisted imaging a standard in healthcare, Brainomix bridges the gap between technology and clinical application.
Future goals and US expansion
The recent investment will help Brainomix expand into the United States. The company has obtained ten FDA clearances. Brainomix aims to broaden its AI technology to new disease areas. This will improve diagnostic speed and accessibility. With over 75 employees, Brainomix plans to scale its operations in Oxford. They will also expand their international commercial team. The company will recruit specialists in AI development, regulatory affairs, and business development. This growth initiative will enhance market penetration. It will also extend Brainomix’s influence in medical imaging.
Brainomix has also developed the Brainomix 360 e-Lung technology. The FDA has approved it for predicting disease progression in lung fibrosis. Brainomix is collaborating with Boehringer Ingelheim, a leader in lung fibrosis treatments. They are assessing the real-world effectiveness of e-Lung. This will improve identification and access to treatment for patients with progressive lung fibrosis.
Competitive landscape
In the stroke AI imaging technology space, Brainomix competes with US-based companies RapidAI and Viz.ai. However, it leads in Europe, with its technology widely implemented in Hungary, Wales, and across most English stroke units. This widespread adoption shows the confidence healthcare institutions have in Brainomix’s AI platform. AI tools are primarily used for research in lung fibrosis. This positions Brainomix to expand its clinical adoption and leverage its stroke expertise for broader medical applications. By integrating AI-driven solutions across different disease areas, the company aims to revolutionise diagnostic imaging.
Industry and investor support
Dr. Papadakis expressed his gratitude, stating, “We would like to thank all the investors that participated, including Parkwalk and Boehringer Ingelheim Venture Fund for their continued support, and welcome Hostplus, all of whom recognise the transformative impact that our technology can have on treatment for stroke and lung fibrosis patients. We will continue to harness our position and experience as a European market leader to achieve broad success in the US, helping improve patient care and access to life-changing therapies.”
John Pearson, Chief Investment Officer at Parkwalk, highlighted the growing impact of AI in healthcare, stating, “The potential for AI-powered platforms in healthcare to revolutionise diagnosis and treatment decisions is clear. Brainomix has successfully demonstrated its platform imaging software is able to deliver both significant societal impact and strong growth for investors. Parkwalk is excited to continue supporting a company that is creating comprehensive solutions to critical needs and implementing them at scale.”
Dr. Oliver Reuss, Investment Manager of BIVF and Director of the Brainomix Board, praised the company, saying, “Brainomix has demonstrated an unparalleled track record of successfully delivering AI solutions into stroke clinical practice, and they are now doing it again in lung fibrosis. As a strategic investor with a shared vision to enhance care for lung disease, we believe Brainomix has the potential to improve the identification and access to treatment for people with lung fibrosis.”
The post Brainomix secures £14M to expand AI imaging technology in strokes and lung fibrosis appeared first on Tech Funding News.